Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

FLT3 Ligand Is Required for Full Activation of FLT3 Mutants.

Rui Zheng, PhD, Obdulio Piloto, Ph.D., Donald Small, M.D., Ph.D.

Blood (2006) 108 (11): 617.

https://doi.org/10.1182/blood.V108.11.617.617

Published: 2006

Journal Articles

FLT3 Mutant Activation Is Still Dependent on FLT3 Ligand.

Rui Zheng, PhD, Obdulio Piloto, BS, Donald Small, MD, PhD

Blood (2005) 106 (11): 2294.

https://doi.org/10.1182/blood.V106.11.2294.2294

Published: 2005

Journal Articles

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression

Rui Zheng, Alan D. Friedman, Mark Levis, Li Li, Edward G. Weir, Donald Small

Blood (2004) 103 (5): 1883–1890.

https://doi.org/10.1182/blood-2003-06-1978

Published: 2004

Journal Articles

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells

Rui Zheng, Mark Levis, Obdulio Piloto, Patrick Brown, Brenda R. Baldwin, Norbert C. Gorin, Miloslav Beran, Zhenping Zhu, Dale Ludwig, Dan Hicklin, Larry Witte, Yiwen Li, Donald Small

Blood (2004) 103 (1): 267–274.

https://doi.org/10.1182/blood-2003-06-1969

Published: 2004

Journal Articles

Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations

Rui Zheng, Alan D. Friedman, Donald Small

Blood (2002) 100 (12): 4154–4161.

https://doi.org/10.1182/blood-2002-03-0936

Published: 2002

Journal Articles

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Mark Levis, Jeffrey Allebach, Kam-Fai Tse, Rui Zheng, Brenda R. Baldwin, B. Douglas Smith, Susan Jones-Bolin, Bruce Ruggeri, Craig Dionne, Donald Small

Blood (2002) 99 (11): 3885–3891.

https://doi.org/10.1182/blood.V99.11.3885

Published: 2002

NARROW

FLT3 Ligand Is Required for Full Activation of FLT3 Mutants.

FLT3 Mutant Activation Is Still Dependent on FLT3 Ligand.

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells

Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Email alerts

ASH Publications

American Society of Hematology

FLT3 Ligand Is Required for Full Activation of FLT3 Mutants.

FLT3 Mutant Activation Is Still Dependent on FLT3 Ligand.

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells

Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only